The global viral vector development market is expected to enjoy a valuation of US$ 730.7 Million by the end of the year 2023, and further expand at a CAGR of 18.7% to reach a valuation of US$ 4.1 Billion by the year 2033. According to the recent study by Future Market Insights, adeno-associated viral vectors (AAV) are leading the market with an expected share of about 37.0% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 624.7 Million |
| Market Value 2023 | US$ 730.7 Million |
| Market Value 2033 | US$ 4.1 Billion |
| CAGR 2023 to 2033 | 18.7% |
| Market Share of Top 5 Countries | 57.5% |
| Key Market Players List | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG ; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; and AGC Biologics |
Since viral vectors are created utilising animal cell cultures, and in some cases insect cell cultures, they are essentially made from viruses which naturally infect human or other mammalian cells. The last ten years have seen a tremendous advancement in manufacturing techniques for the development of clinical grade viral vectors. This is crucial for gene therapy methods implemented to the treatment of congenital or acquired disorders. AAV and lentiviral vectors are currently being used more frequently for in vivo and ex vivo gene delivery, respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for viral vector development was approximately 35.5% of the overall ~US$ 30.86 Million of the global cancer gene therapy market in 2022.
The sale of viral vector development expanded at a CAGR of 14.5% from 2017 to 2022.
Traditional medicine researchers and the medical world have long believed that hereditary disorders are incurable. Genetic therapy, on the other hand, heralded a new era in medicine by offering the chance to fix the damaged genes that cause certain inherited illnesses.
Adeno-associated virus, often known as AAV, is frequently utilised as a carrier in the gene therapy procedure. The products made with viral vectors are proving to be suitable for the market because gene therapy has numerous potential applications in the medical sciences. Many biopharmaceutical companies are engaged in manufacturing and supply, which could be aimed at balancing the demand-supply ratio.
Despite the unexpected disruption of the world economy for all products during the pandemic years that followed the outbreak of COVID-19 infections, it offered tremendous chances for the viral vector CDMO business to expand globally. The search for a therapeutic approach and a vaccine to prevent the causal pathogen's rapid spread involved numerous research centres and private biopharmaceutical businesses.
It was necessary to cultivate a novel coronavirus in order to build any kind of countermeasure, which raised the need for viral vector products. Private manufacturing firms and public institutions developing viral vectors drove the production and supply of all varieties of viral vectors, including recombinant adenoviral vectors.
The AAV-based vaccine for COVID-19 infection prevention is currently been developed by a number of businesses and state organisations. The global viral vector market will be driven by the COVID-19, which is the subject of extensive research to produce a more effective vaccination for the upcoming years. Thus, owing to the aforementioned factors, the global viral vector development market is expected to grow at a CAGR of 18.7% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 13.21% |
| Jul - Dec (H2), 2021 (A) | 16.95% |
| Jan - Jun (H1),2022 Projected (P) | 13.65% |
| Jan - Jun (H1),2022 Outlook (O) | 14.28% |
| Jul - Dec (H2), 2022 Outlook (O) | 17.66% |
| Jul - Dec (H2), 2022 Projected (P) | 16.92% |
| Jan - Jun (H1), 2023 Projected (P) | 15.08% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 63↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 107↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 74↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 71↑ |
Gene therapy is necessary to repair suppressed and malfunctioning genes in human cells or tissues and return the abnormality to normal levels. Viral vector technology is used to cultivate the gene, and this business has grown significantly for many private players. For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process.
When it comes to 2D planer technologies, scaling out of adherent cell systems is a common strategy that has been applied up until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period.
The synthesis of viral vectors using cell culture technology has been successfully modified to satisfy the demands of both early and advanced clinical trial phases. Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen.
Presently, great progress is being made in the generation of cell lines that can create inducible or constitutively expressed lentiviral vectors that grow in suspension. Recently, the first batch of lentiviral vectors generated by reliable producer cell lines was utilised in a clinical trial setting.
With extensive safety and efficacy data gathered from various clinical trials, it is evident that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period.
Principal Consultant
The deployment of exceedingly complex procedures was brought about by the need for clinical-grade, thoroughly polished final products. For the initial set of production units, such advanced technological techniques require a significant investment from the viral vector firms.
The primary barrier to the rapid development of viral vectors for varied purposes remains the strict government requirements for sanctioning any new development related to the healthcare sector.
The global viral vector development market's expansion is undoubtedly constrained by the lack of enough good laboratories for the testing and approval of essential raw materials.
Due to its superior safety profile and effective transduction to a variety of target tissues, adeno-associated virus (AAV) has become a major platform for the delivery of genes for the treatment of many disorders. Viral vectors are less effective than recombinant protein treatments in large-scale production and long-term preservation, which results in lower yields, a modest level of purity, and a shorter shelf life.
The cost-effective manufacture of viral vectors remains a challenge despite notable clinical and commercial accomplishments, primarily because it is unclear how different methods affect the quality and shelf-life of AAV products.
This is because AAV gene therapy's clinical progress has outpaced its CMC, manufacturing, and formulation development. These factors are expected to restrain the market expansion over the forecast period.
| Country | The USA |
|---|---|
| Market Share (2023) | 33.5% |
| Market Share (2033) | 31.8% |
| BPS Analysis | -169 |
| Country | China |
|---|---|
| Market Share (2023) | 6.7% |
| Market Share (2033) | 4.2% |
| BPS Analysis | -245 |
| Country | UK |
|---|---|
| Market Share (2023) | 6.4% |
| Market Share (2033) | 7.1% |
| BPS Analysis | 63 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.8% |
| Market Share (2033) | 7.6% |
| BPS Analysis | 177 |
| Country | Japan |
|---|---|
| Market Share (2023) | 4.8% |
| Market Share (2033) | 2.7% |
| BPS Analysis | -208 |
The USA dominates the globe with a total market share of about 33.1% in 2022, and is expected to continue to experience the same growth throughout the forecast period.
One of the key reasons fueling the market's growth throughout the forecast period is the rising number of patients choosing gene therapy to treat diseases like hemophilia, heart disease, diabetes, cystic fibrosis, cancer, and AIDS. The increased development of gene therapy has increased the demand for plasmid DNA. Collaborations between businesses, various organizations, academic institutions, and nonprofit groups are growing as they work to create viral vectors and plasmid DNA. These elements encourage market expansion in the United States.
Germany held a market share of nearly 5.6% in the global viral vector development market in 2022.
In February 2020, the US production facility of the German-based viral vector company Vibalogics, CDMO was established. By providing CDMO viral vector, this facility in Massachusetts that was developed with a $150 million investment, is anticipated to seize the North American market. With such expansions taking place among the key players into developing regions, the market is set to expand in Germany
China held a share of around 7.1% in the global market, in 2022.
In order to increase its capabilities and production capacity, VectorBuilder stated in April 2022 that it would build a $500 million gene delivery and research facility in Guangzhou, China.
The "Gene Delivery Research and Manufacturing Campus," as it has been dubbed by contract development manufacturing organization (CDMO) VectorBuilder, which offers gene delivery systems, will be constructed over the course of four years.
The campus will have 30 production suites, according to the company, that can produce plasmids, cell lines, adeno-associated virus (AAV), lentivirus, messenger RNA (mRNA), and other viral and non-viral vectors.
Such advancements within the country are expected to propel the growth of the overall market throughout the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Adeno-associated viral vectors are set to hold a share of around 37.0% in the global market, in 2023.
Adeno-associated viral vectors are the most efficient way to transfer genes to treat a wide range of human illnesses. Recent advancements in the design of therapeutically appealing AAV capsids, genome optimization, and the use of advanced biotechnologies have resulted in a considerable expansion of the area of gene therapy. Two AAV-based drugs have been approved by regulators in the US or Europe, proving the clinical and preclinical efficacy of AAV as the ideal therapeutic vector for gene editing, gene silencing, and gene substitution.
The stable expression system will hold a global market share of around 85.80% in 2023.
Owing of its intricacy, viral vector manufacturing is still evolving. The majority of researchers acknowledge that obtaining sufficient yields of functional capsids with the required genetic payload represents the biggest challenge. The most commonly used strategy is transient transfection, which effectively creates a cell line for every production cycle or a "cell factory" for a single production cycle. A stable and optimised manufacturing cell line, analogous to the ones used for other biologics, would provide a more reliable approach and be scalable if cells were cultured in suspension. Over the anticipated years, this is expected to increase the segment value.
Gene therapy applications are set to hold a market share of around 55.1% in the global market in 2023.
Because viruses have proven to be particularly effective at entering cells, vectors are frequently created from them. All viral genes are removed from vectors before they are changed to solely carry therapeutic genes, making them safe to employ. Three different types of vectors—adeno-associated virus (AAV) vectors, adenovirus vectors, or lentivirus vectors—are used by almost all gene therapies currently on the market.
Viral vectors are used in gene therapy to address more than just symptoms. With the genetic information they contain, vectors can modify a cell's behavior and target the underlying cause of a disease. They are frequently used for uncommon genetic disorders for whom there are few to no other effective treatments, and they normally only need to be delivered once.
Academic and Research Institutes are set to hold a significant market share of around 45.7% globally, in 2023.
According to data provided by the WHO and FDA, by February 2022, there were 114 candidate vaccines in clinical trials, 75 animal preclinical trials, and 14 vaccinations that have been licensed for emergency use. In order to develop drug candidates more efficiently, with enhanced therapeutic potential and greater access for patients worldwide, there has been a surge in collaborations between pharmaceutical companies and academic and research institutes, thus propelling segment growth within the overall market.
Viral Vector Development Market:
| Attributes | Viral Vector Development Market |
|---|---|
| CAGR (2023 to 2033) | 18.7% |
| Market Value (2023) | US$ 730.7 Million |
| Growth Factor | Growing developments in gene therapy safety, immune response control, and cost reduction in manufacturing are the key market drivers. Regulators have used reducing the empty-to-full capsid ratio as justification for removing clinical holds on gene-therapy products that had previously encountered safety problems. |
| Key Market Trend | Focus on development of novel gene therapies. |
Cancer Gene Therapy Market:
| Attributes | Cancer Gene Therapy Market |
|---|---|
| CAGR (2023 to 2033) | 10.1% |
| Market Value (2023) | US$ 2.2 Billion |
| Growth Factor | Developments in oncolytic viral therapy and advancements in technology are the key drivers of the market. Rising investments in cancer research and increasing demand for novel biologics are further propelling factors adding towards market expansion. |
| Key Trend | Governments are expanding awareness programs for cancer research. There is also an increasing ethical acceptability of gene therapy owed to favorable results obtained through clinical trials. |
Oncology Blood Testing Market:
| Attributes | Oncology Blood Testing Market |
|---|---|
| CAGR (2023 to 2033) | 15.2% |
| Market Value (2023) | US$ 4.44 Billion |
| Growth Factor | Companies offer a variety of molecular decision support systems that combine genomic and clinical data to fill gaps in precision medicine practice, increasing demand for oncology blood tests. |
| Key Trend | The significant market trends are increasing cases of hematologic or blood cancer, increasing demand for oncology blood tests due to advantageous and straightforward reimbursement policies, and increasing awareness of advanced treatment options. |
The market for the production of plasmid DNA and viral vector CDMO has become extremely competitive in recent years as a result of the introduction of numerous companies in these industries. The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the viral vector development market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Virus, Application, Expression System, End User, and Region |
| Key Companies Covered | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; AGC Biologics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The viral vector development market is pegged at a value of US$ 730.7 million in 2023.
The viral vector development market is estimated to reach US$ 4.1 billion by 2033.
Sales of viral vector development are anticipated to surge at a noteworthy CAGR of 18.7% through 2033.
The United States has turned into a key hub in the market with a sizeable share of 33.1% in 2022.
The viral vector development market reached a value of US$ 624.7 million In 2022.
1. Executive Summary | Viral Vector Development Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Market Innovation / Development Trends 4. Key Success Factors 4.1. Disease Epidemiology, by Region 4.2. Technological Assessment 4.3. Regulatory Landscape 4.4. Promotional Strategies, By Key Players 4.5. PESTEL Analysis 4.6. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Cancer Gene Therapy Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Prevalence of Chronic Diseases 5.2.2. Increasing Research and Development in Oncology Gene Therapy 5.2.3. Rising Investments in Viral Gene Therapy 5.2.4. New Product Launch Activities 5.2.5. Technological Advancements 5.2.6. Regulatory Impositions 5.2.7. Growing CMO/CDMO Activities 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Virus 6.1.2. By Expression System 6.1.3. By Application 6.1.4. By End User 6.1.5. By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Size (US$ Million) Analysis and Forecast, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Virus 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Virus, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Virus, 2023 to 2033 8.3.1. Lentiviral Vectors 8.3.2. Adenoviral Vectors 8.3.3. Adeno-Associated Viral Vectors 8.3.4. Retrovirus 8.4. Market Attractiveness Analysis By Virus 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Expression System 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Expression System, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Expression System, 2023 to 2033 9.3.1. Transient 9.3.2. Stable 9.4. Market Attractiveness Analysis By Expression System 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Application, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 10.3.1. Gene Therapy 10.3.2. Vaccines 10.3.3. Cancer Therapy 10.3.4. Others 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2023 to 2033 11.3.1. Biotechnology Companies 11.3.2. Pharmaceutical Companies 11.3.3. Contract Research Organization (CRO) 11.3.4. Academic and Research Institutes 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Virus 13.3.3. By Expression System 13.3.4. By Application 13.3.5. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Virus 13.4.3. By Expression System 13.4.4. By Application 13.4.5. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. USA Market Analysis 13.8.1.1. .Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Virus 13.8.1.2.2. By Expression System 13.8.1.2.3. By Application 13.8.1.2.4. By End User 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Virus 13.8.2.2.2. By Expression System 13.8.2.2.3. By Application 13.8.2.2.4. By End User 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Virus 14.3.3. By Expression System 14.3.4. By Application 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Virus 14.4.3. By Expression System 14.4.4. By Application 14.4.5. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Virus 14.8.1.2.2. By Expression System 14.8.1.2.3. By Application 14.8.1.2.4. By End User 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Virus 14.8.2.2.2. By Expression System 14.8.2.2.3. By Application 14.8.2.2.4. By End User 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Virus 14.8.3.2.2. By Expression System 14.8.3.2.3. By Application 14.8.3.2.4. By End User 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Virus 15.3.3. By Expression System 15.3.4. By Application 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Virus 15.4.3. By Expression System 15.4.4. By Application 15.4.5. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Virus 15.8.1.2.2. By Expression System 15.8.1.2.3. By Application 15.8.1.2.4. By End User 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. B By Virus 15.8.2.2.2. By Expression System 15.8.2.2.3. By Application 15.8.2.2.4. By End User 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Virus 15.8.3.2.2. By Expression System 15.8.3.2.3. By Application 15.8.3.2.4. By End User 15.8.4. United Kingdom Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Virus 15.8.4.2.2. By Expression System 15.8.4.2.3. By Application 15.8.4.2.4. By End User 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Virus 15.8.5.2.2. By Expression System 15.8.5.2.3. By Application 15.8.5.2.4. By End User 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Virus 15.8.6.2.2. By Expression System 15.8.6.2.3. By Application 15.8.6.2.4. By End User 15.8.7. Russia Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Virus 15.8.7.2.2. By Expression System 15.8.7.2.3. By Application 15.8.7.2.4. By End User 16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Virus 16.3.3. By Expression System 16.3.4. By Application 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Virus 16.4.3. By Expression System 16.4.4. By Application 16.4.5. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Virus 16.8.1.2.2. By Expression System 16.8.1.2.3. By Application 16.8.1.2.4. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Virus 16.8.2.2.2. By Expression System 16.8.2.2.3. By Application 16.8.2.2.4. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Virus 16.8.3.2.2. By Expression System 16.8.3.2.3. By Application 16.8.3.2.4. By End User 17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Virus 17.3.3. By Expression System 17.3.4. By Application 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Virus 17.4.3. By Expression System 17.4.4. By Application 17.4.5. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Virus 17.8.1.2.2. By Expression System 17.8.1.2.3. By Application 17.8.1.2.4. By End User 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Virus 17.8.2.2.2. By Expression System 17.8.2.2.3. By Application 17.8.2.2.4. By End User 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Virus 17.8.3.2.2. By Expression System 17.8.3.2.3. By Application 17.8.3.2.4. By End User 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Virus 17.8.4.2.2. By Expression System 17.8.4.2.3. By Application 17.8.4.2.4. By End User 18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Virus 18.3.3. By Expression System 18.3.4. By Application 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Virus 18.4.3. By Expression System 18.4.4. By Application 18.4.5. By End User 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Virus 18.8.1.2.2. By Expression System 18.8.1.2.3. By Application 18.8.1.2.4. By End User 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Virus 18.8.2.2.2. By Expression System 18.8.2.2.3. By Application 18.8.2.2.4. By End User 19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. North Africa 19.3.1.4. South Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Virus 19.3.3. By Expression System 19.3.4. By Application 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Virus 19.4.3. By Expression System 19.4.4. By Application 19.4.5. By End User 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Virus 19.8.1.2.2. By Expression System 19.8.1.2.3. By Application 19.8.1.2.4. By End User 19.8.2. Türkiye Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Virus 19.8.2.2.2. By Expression System 19.8.2.2.3. By Application 19.8.2.2.4. By End User 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Virus 19.8.3.2.2. By Expression System 19.8.3.2.3. By Application 19.8.3.2.4. By End User 19.8.4. North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Virus 19.8.4.2.2. By Expression System 19.8.4.2.3. By Application 19.8.4.2.4. By End User 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Thermo Fisher Scientific Inc 21.3.1.1. Overview 21.3.1.2. Product Overview 21.3.1.3. Sales Footprint 21.3.1.4. Key Financials 21.3.1.5. SWOT Analysis 21.3.1.6. Strategy Overview 21.3.1.6.1. Marketing Strategy 21.3.1.6.2. Product Strategy 21.3.1.6.3. Channel Strategy 21.3.2. Charles River (Cobra Biologics) 21.3.2.1. Overview 21.3.2.2. Product Overview 21.3.2.3. Sales Footprint 21.3.2.4. Key Financials 21.3.2.5. SWOT Analysis 21.3.2.6. Strategy Overview 21.3.2.6.1. Marketing Strategy 21.3.2.6.2. Product Strategy 21.3.2.6.3. Channel Strategy 21.3.3. NOVASEP 21.3.3.1. Overview 21.3.3.2. Product Overview 21.3.3.3. Sales Footprint 21.3.3.4. Key Financials 21.3.3.5. SWOT Analysis 21.3.3.6. Strategy Overview 21.3.3.6.1. Marketing Strategy 21.3.3.6.2. Product Strategy 21.3.3.6.3. Channel Strategy 21.3.4. uniQure N.V 21.3.4.1. Overview 21.3.4.2. Product Overview 21.3.4.3. Sales Footprint 21.3.4.4. Key Financials 21.3.4.5. SWOT Analysis 21.3.4.6. Strategy Overview 21.3.4.6.1. Marketing Strategy 21.3.4.6.2. Product Strategy 21.3.4.6.3. Channel Strategy 21.3.5. Waisman Biomanufacturing 21.3.5.1. Overview 21.3.5.2. Product Overview 21.3.5.3. Sales Footprint 21.3.5.4. Key Financials 21.3.5.5. SWOT Analysis 21.3.5.6. Strategy Overview 21.3.5.6.1. Marketing Strategy 21.3.5.6.2. Product Strategy 21.3.5.6.3. Channel Strategy 21.3.6. Creative Biogene 21.3.6.1. Overview 21.3.6.2. Product Overview 21.3.6.3. Sales Footprint 21.3.6.4. Key Financials 21.3.6.5. SWOT Analysis 21.3.6.6. Strategy Overview 21.3.6.6.1. Marketing Strategy 21.3.6.6.2. Product Strategy 21.3.6.6.3. Channel Strategy 21.3.7. GenScript Biotech Corporation 21.3.7.1. Overview 21.3.7.2. Product Overview 21.3.7.3. Sales Footprint 21.3.7.4. Key Financials 21.3.7.5. SWOT Analysis 21.3.7.6. Strategy Overview 21.3.7.6.1. Marketing Strategy 21.3.7.6.2. Product Strategy 21.3.7.6.3. Channel Strategy 21.3.8. Novartis AG 21.3.8.1. Overview 21.3.8.2. Product Overview 21.3.8.3. Sales Footprint 21.3.8.4. Key Financials 21.3.8.5. SWOT Analysis 21.3.8.6. Strategy Overview 21.3.8.6.1. Marketing Strategy 21.3.8.6.2. Product Strategy 21.3.8.6.3. Channel Strategy 21.3.9. Merck KGaA 21.3.9.1. Overview 21.3.9.2. Product Overview 21.3.9.3. Sales Footprint 21.3.9.4. Key Financials 21.3.9.5. SWOT Analysis 21.3.9.6. Strategy Overview 21.3.9.6.1. Marketing Strategy 21.3.9.6.2. Product Strategy 21.3.9.6.3. Channel Strategy 21.3.10. Takara Bio, Inc. 21.3.10.1. Overview 21.3.10.2. Product Overview 21.3.10.3. Sales Footprint 21.3.10.4. Key Financials 21.3.10.5. SWOT Analysis 21.3.10.6. Strategy Overview 21.3.10.6.1. Marketing Strategy 21.3.10.6.2. Product Strategy 21.3.10.6.3. Channel Strategy 21.3.11. FUJIFILM Diosynth Biotechnologies 21.3.11.1. Overview 21.3.11.2. Product Overview 21.3.11.3. Sales Footprint 21.3.11.4. Key Financials 21.3.11.5. SWOT Analysis 21.3.11.6. Strategy Overview 21.3.11.6.1. Marketing Strategy 21.3.11.6.2. Product Strategy 21.3.11.6.3. Channel Strategy 21.3.12. LONZA 21.3.12.1. Overview 21.3.12.2. Product Overview 21.3.12.3. Sales Footprint 21.3.12.4. Key Financials 21.3.12.5. SWOT Analysis 21.3.12.6. Strategy Overview 21.3.12.6.1. Marketing Strategy 21.3.12.6.2. Product Strategy 21.3.12.6.3. Channel Strategy 21.3.13. Danaher Corp. (Aldevron) 21.3.13.1. Overview 21.3.13.2. Product Overview 21.3.13.3. Sales Footprint 21.3.13.4. Key Financials 21.3.13.5. SWOT Analysis 21.3.13.6. Strategy Overview 21.3.13.6.1. Marketing Strategy 21.3.13.6.2. Product Strategy 21.3.13.6.3. Channel Strategy 21.3.14. Sirion Biotech GmbH 21.3.14.1. Overview 21.3.14.2. Product Overview 21.3.14.3. Sales Footprint 21.3.14.4. Key Financials 21.3.14.5. SWOT Analysis 21.3.14.6. Strategy Overview 21.3.14.6.1. Marketing Strategy 21.3.14.6.2. Product Strategy 21.3.14.6.3. Channel Strategy 21.3.15. AGC Biologics 21.3.15.1. Overview 21.3.15.2. Product Overview 21.3.15.3. Sales Footprint 21.3.15.4. Key Financials 21.3.15.5. SWOT Analysis 21.3.15.6. Strategy Overview 21.3.15.6.1. Marketing Strategy 21.3.15.6.2. Product Strategy 21.3.15.6.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Viral Vector Development Market
